273 related articles for article (PubMed ID: 20235388)
1. Novel agents target existing tumor vasculature.
Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
[No Abstract] [Full Text] [Related]
2. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of the tumor vasculature.
Tozer GM; Bicknell R
Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
[TBL] [Abstract][Full Text] [Related]
4. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
5. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
6. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
7. Metronomic chemotherapy: Back to the future!
André N; Padovani L; Verschuur A
Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
[TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature as target for therapeutic intervention.
Fens MH; Storm G; Schiffelers RM
Expert Opin Investig Drugs; 2010 Nov; 19(11):1321-38. PubMed ID: 20946091
[TBL] [Abstract][Full Text] [Related]
9. Potential role of vascular targeted therapy to combat against tumor.
Chen B; Jin H; Wu K
Expert Opin Drug Deliv; 2009 Jul; 6(7):719-26. PubMed ID: 19538038
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis research: guidelines for translation to clinical application.
Folkman J; Browder T; Palmblad J
Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
[TBL] [Abstract][Full Text] [Related]
11. Taking down tumors: vascular disrupting agents entering clinical trials.
O'Hanlon LH
J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
[No Abstract] [Full Text] [Related]
12. Angiogenesis. A boost for tumor starvation.
Marx J
Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
[No Abstract] [Full Text] [Related]
13. Closing in on cancer.
Park A
Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
[No Abstract] [Full Text] [Related]
14. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenesis: new frontiers in therapeutic development.
LaMontagne KR
Angiogenesis; 2005; 8(4):285-7. PubMed ID: 16400519
[No Abstract] [Full Text] [Related]
16. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
17. Cancer angiogenesis: targeting the heel of Achilles.
Dass CR; Choong PF
J Drug Target; 2008 Jul; 16(6):449-54. PubMed ID: 18604657
[TBL] [Abstract][Full Text] [Related]
18. Cancer research. Obstacle for promising cancer therapy.
Marx J
Science; 2002 Feb; 295(5559):1444. PubMed ID: 11859164
[No Abstract] [Full Text] [Related]
19. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
